Given the concerted role of these three fitness genes in transduction of the TNFR1-induced NF-κB pathway and cross-talk with cIAP-mediated death signaling pathways, we postulate that other cancer types dependent on NF-κB pathway genes are also likely to respond to IAP inhibitors. The gene discussed is NFKB1; the disease is cancer.